This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

While this is expected to improve with the second dose, this important finding may help influence the design of future vaccination strategies, with further work needed to determine the optimal interval between vaccine doses in certain groups.

The team from the University of Oxford’s MRC-Weatherall Institute of Molecular Medicine (MRC-WIMM) Molecular Haematology Unit studied 60 patients with chronic myeloid blood cancers under the care of the Myeloid Team at the Churchill Hospital, Oxford University Hospitals NHS Foundation Trust.

The study, published in the British Journal of Haematology, was supported by the NIHR Oxford Biomedical Research Centre.

Read the full story on the NIHR Oxford Biomedical Research Centre website

Research Healthcare Innovation COVID-19